aibio
Distress ·
Neurogene delays quarterly report for period ended September 30, 2024
The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.
NGNE Neurogene Inc.
Neurogene (NGNE) news NGNE offering news
Latest Neurogene news
- Financings
Neurogene agrees to $200.0 million private placement at $50.00 per share
Neurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors.
Neurogene annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $925,000 |
| Research and development | $75.0 million | $60.9 million |
| Net income (loss) | -$90.4 million | -$75.1 million |
| Cash from operations | -$77.2 million | -$70.6 million |
| Cash and equivalents | $103.8 million | $136.6 million |
| Short-term investments | $165.2 million | $175.8 million |
Questions about Neurogene
Has Neurogene raised money recently?
Our latest story on this, dated Nov 4, 2024: "Neurogene agrees to $200.0 million private placement at $50.00 per share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Neurogene?
Neurogene Inc. trades under the ticker NGNE on NASDAQ.
Where is Neurogene listed?
Neurogene Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A3EX79; LSX:A3EX79.
What is the SEC CIK of Neurogene?
The SEC Central Index Key (CIK) for Neurogene Inc. is 1404644. Its filings are on SEC EDGAR.
How many shares does Neurogene have outstanding?
20,011,382 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Neurogene listed under?
Our directory records Neurogene Inc. under United States.
What does Neurogene do?
Our directory classifies Neurogene Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Neurogene?
The ISIN recorded for Neurogene Inc. is US64135M1053.
Does aibio.space cover Neurogene?
aibio.space lists Neurogene Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Neurogene's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Neurogene profitable?
Neurogene Inc. reported a net loss of $90.4 million for the fiscal year ended Dec 31, 2025, and used $77.2 million of cash in operations, per its annual report to the SEC.
How much does Neurogene spend on research and development?
$75.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Neurogene have?
$225.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Neurogene (NGNE) stock news?
Our latest story on Neurogene, dated Nov 14, 2024: "Neurogene delays quarterly report for period ended September 30, 2024". The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. Source.
Is Neurogene in financial distress?
Our latest distress story, dated Nov 14, 2024: "Neurogene delays quarterly report for period ended September 30, 2024". The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. Source.
Investor discussion: Neurogene
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Neurogene Inc.
- CIK
- 1404644
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 535 W 24TH STREET, NEW YORK, NY, 10011
- Phone
- (877) 237-5020
- Shares outstanding
- 20,011,382 as of 2026-08-07 (10-Q filed 2026-08-11)
- Former names
- Neoleukin Therapeutics, Inc.; AQUINOX PHARMACEUTICALS, INC; AQUINOX PHARMACEUTICALS (USA) INC
Recent filings
Listing details
- Company
- Neurogene Inc.
- Ticker
- NGNE
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US64135M1053
- Other listed symbols
- LS:A3EX79; LSX:A3EX79
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction